Text this: Corrigendum to “WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM” [Kidney International Reports Volume 9, Issue 4, Supplement, April 2024, Pages S368-S369]